REHOVOT, Israel and BRIDGEWATER, N.J., May 28, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dr. Dov Tamarkin, Chief Executive Officer, will provide a corporate overview and business update at the Jefferies 2015 Global Healthcare Conference.
|Title:||Jefferies 2015 Global Healthcare Conference|
|Date:||Thursday, June 4|
|Time:||9:00am Eastern Time|
|Location:||Grand Hyatt Hotel, New York City|
About Foamix Pharmaceuticals
Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix Pharmaceuticals' lead product candidate FMX101 for moderate-to-severe acne is a novel topical foam formulation of the antibiotic minocycline. Foamix Pharmaceuticals also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.